Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achieving adequate glycaemic control is an important aim of therapy. Thiazolidinediones, or glitazones, have been used for the treatment of diabetes for a decade. Rosiglitazone and pioglitazone are currently available, however recent concerns around cardiovascular safety have led to restrictions on their use. Initial trials showed treatments with glitazones improved glycaemic control, however long-term outcomes such as cardiovascular events were not measured. Evidence from more recent trials suggests rosiglitazone is associated with an increased risk of cardiovascular events and both glitazones are associated with higher rates of heart failure. This article discusses the evidence behind these concerns and the most recent guidance on use of thiazolidinediones in clinical practice.

Original publication

DOI

10.3399/bjgp09X453440

Type

Journal article

Journal

Br J Gen Pract

Publication Date

07/2009

Volume

59

Pages

520 - 524

Keywords

Diabetes Mellitus, Type 2, Heart Failure, Humans, Hypoglycemic Agents, Meta-Analysis as Topic, Practice Guidelines as Topic, Randomized Controlled Trials as Topic, Risk Factors, Thiazolidinediones